# EDGAR Filing Document

**Accession Number:** 0001876588
**File Stem:** 0001193125-25-237145
**Filing Date:** 2025-10
**Character Count:** 13723
**Document Hash:** a97d272345009a722452a50090c5b935
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-237145.hdr.sgml**: 20251010

**ACCESSION NUMBER**: 0001193125-25-237145

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251010

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251010

**DATE AS OF CHANGE**: 20251010

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZimVie Inc.
- **CENTRAL INDEX KEY:** 0001876588
- **STANDARD INDUSTRIAL CLASSIFICATION:** DENTAL EQUIPMENT & SUPPLIES [3843]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41242
- **FILM NUMBER:** 251388428

**BUSINESS ADDRESS:**
- **STREET 1:** 4555 RIVERSIDE DRIVE
- **CITY:** PALM BEACH GARDEN
- **STATE:** FL
- **ZIP:** 33410
- **BUSINESS PHONE:** 800-342-5454

**MAIL ADDRESS:**
- **STREET 1:** 4555 RIVERSIDE DRIVE
- **CITY:** PALM BEACH GARDEN
- **STATE:** FL
- **ZIP:** 33410

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZB SpinCo Holdings, Inc.
- **DATE OF NAME CHANGE:** 20210803

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): October 10, 2025

## ZimVie Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41242** | **87-2007795** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **4555 Riverside Drive**<br> **Palm Beach Gardens, Florida** | **33410** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (800) 342-5454

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.01 per share | ZIMV | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

As previously disclosed, on July 20, 2025, ZimVie Inc. (the "<u>Company</u>") entered into an Agreement and Plan of Merger (the "<u>Merger Agreement</u>") with Zamboni Parent Inc., a Delaware corporation ("<u>Parent</u>"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("<u>MergerCo</u>"), pursuant to which and subject to the terms and conditions thereof, MergerCo will be merged with and into the Company (the "<u>Merger</u>"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Upon completion of the Merger, the Company will no longer be publicly held. The common stock, par value $0.01 per share, of the Company ("<u>Company Common Stock</u>") will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended. On October 10, 2025, the Company held a special meeting of its stockholders (the "<u>Special Meeting</u>") to vote on the proposals identified in the definitive proxy statement filed with the Securities and Exchange Commission on September 2, 2025, which was first mailed to the Company's stockholders on September 2, 2025.

As of the close of business on September 2, 2025, the record date for the Special Meeting, there were 28,210,715 shares of Company Common Stock outstanding and entitled to vote at the Special Meeting. 20,701,308 shares of Company Common Stock, representing approximately 73.38% of all of the issued and outstanding Company Common Stock entitled to vote, were represented at the Special Meeting. The tables below detail the final voting results for each proposal:

1. The proposal to adopt the Merger Agreement (the " <u>Merger Agreement Proposal</u> "). The Company's stockholders approved the Merger Agreement Proposal as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 20,615,874 | 29,686 | 55,748 | 0 |

---

2. The proposal to approve, by advisory (non-binding) vote, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the consummation of the Merger (the " <u>Advisory Compensation Proposal</u> "). The Company's stockholders approved, on an advisory (non-binding) basis, the Advisory Compensation Proposal as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 16,997,513 | 3,664,375 | 39,420 | 0 |

---

In connection with the Special Meeting, the Company also solicited proxies with respect to the adjournment of the Special Meeting for the purpose of soliciting additional proxies if there were not sufficient votes at the Special Meeting to approve the Merger Agreement Proposal (the "<u>Adjournment Proposal</u>"). As there were sufficient votes at the time of the Special Meeting to approve the Merger Agreement Proposal, the Adjournment Proposal was unnecessary and such proposal was not submitted to the Company's stockholders for approval at the Special Meeting.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

On October 10, 2025, the Company issued a press release announcing the results of the above mentioned stockholder vote at the Special Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit<br>Number | Description of Exhibit |
| 99.1 | [Press Release, dated October 10, 2025](d21325dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ZimVie Inc. | ZimVie Inc. |
| Date: October 10, 2025 | By: | /s/ Heather Kidwell |
|  | Name: | Heather Kidwell |
|  | Title: | Senior Vice President,<br> Chief Legal, Compliance and Human Resources<br> Officer and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1** 

**FOR IMMEDIATE RELEASE** 

**October 10, 2025** 

**ZIMVIE STOCKHOLDERS VOTE TO** 

**APPROVE ACQUISITION BY ARCHIMED** 

PALM BEACH GARDENS, Florida, October 10, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. ("ZimVie") (Nasdaq: ZIMV) today announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the "Merger") pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025 (the "Merger Agreement").

The parties now expect the Merger to close on October 20, 2025, subject to the satisfaction of all conditions in the Merger Agreement.

**About ZimVie** 

ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

**About ARCHIMED** 

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. For more information about ARCHIMED, please visit www.archimed.group.

------

**Cautionary Note Regarding Forward-Looking Statements** 

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie's expectations, plans, intentions, strategies or prospects, including expected benefits of the proposed transaction. Generally, the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," "could," "would," "predicts," "potential," "strategy," "future," "opportunity," "work toward," "intends," "guidance," "confidence," "positioned," "design," "strive," "continue," "track," "look forward to" and similar expressions used in this release are intended to identify forward-looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.

Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.

These risks, uncertainties and changes in circumstances include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all; (ii) the possibility that any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived; (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction; (iv) the effect of the announcement or pendency of the proposed transaction on ZimVie's ability to attract, motivate or retain key executives and employees, its ability to maintain relationships with its customers, suppliers and other business counterparties, or its operating results and business generally; (v) risks related to the proposed transaction diverting management's attention from ZimVie's ongoing business operations; (vi) the risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay; and (vii) (A) any other risks discussed in ZimVie's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "Annual Report") and ZimVie's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 (the "Quarterly Reports") filed by ZimVie with the Securities and Exchange Commission (the "SEC"), and, in particular, the risk factors set forth under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Annual Report and the Quarterly Reports and (B) other risk factors identified from time to time in other filings with the SEC. Filings with the SEC are available on the SEC's website at <u>http://www.sec.gov</u>.

**Media Contact Information:** 

**ZimVie** 

Grace Flowers • <u>Grace.Flowers@ZimVie.com</u>

(561) 319-6130

------

**Investor Contact Information:** 

**Gilmartin Group LLC** 

Webb Campbell • <u>Webb@gilmartinir.com</u>